Agentic AI was a point of emphasis on the first day of the 2025 Veeva Commercial summit held in Madrid, Spain.
Pharmaceutical Technology on MSN
Eli Lilly and NVIDIA to build pharma’s “most powerful” supercomputer
"Eli Lilly and NVIDIA to build pharma’s “most powerful” supercomputer" was originally created and published by Pharmaceutical ...
Industry leaders say uncertainty in funding, clinical development and manufacturing is driving companies to embrace digital transformation, streamlined operations and strategic partnerships to ...
Tariffs increase operational costs by raising prices for raw materials, APIs, and finished drugs, complicating logistics and ...
Data from Storyful found that users’ fears around AI in the therapy space are widespread. The report noted that one user on Reddit called AI driven therapy a “control system,” while others warned of ...
The pharmaceutical world offers a valuable blueprint on how to harness AI’s efficiency while protecting trust, ethics and above all, people.
Market opportunities arise from the growing need for modernization and compliance assurance in FDA-regulated industries focusing on data integrity. Emphasizing cloud computing, automation, and mobile ...
Mebarki (SGD Pharma): One of our very important innovations is Sealian, which is a unique internal treatment that confers additional functionality to the vial, and for which we have a strong ...
Pharmaceutical Technology on MSN
Cencora to invest $1bn in US pharma distribution network
Cencora is set to invest $1bn by 2030 for expanding its US pharmaceutical distribution network, adding resilience and ...
Silo Pharma Inc (NASDAQ:SILO) announced a new exclusive license agreement with Medspray Pharma BV for its proprietary patented soft mist nasal spray technology, the delivery mechanism selected for ...
In today’s digitally transformed world, technology plays a critical role in how pharmaceutical companies do business. From drug discovery to manufacturing and commercialization, technology is powering ...
Novo Nordisk was a pioneer in developing GLP-1 drugs for metabolic disorders, but its products are still mainly once-weekly injections. The Danish pharmaceutical giant is putting up $285 million to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results